[go: up one dir, main page]

WO2021236579A1 - Administration de composants de membrane amniotique à des épithéliums oculaires pour la cicatrisation de plaies - Google Patents

Administration de composants de membrane amniotique à des épithéliums oculaires pour la cicatrisation de plaies Download PDF

Info

Publication number
WO2021236579A1
WO2021236579A1 PCT/US2021/032878 US2021032878W WO2021236579A1 WO 2021236579 A1 WO2021236579 A1 WO 2021236579A1 US 2021032878 W US2021032878 W US 2021032878W WO 2021236579 A1 WO2021236579 A1 WO 2021236579A1
Authority
WO
WIPO (PCT)
Prior art keywords
amniotic
particles
conformer
ocular device
stem cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/032878
Other languages
English (en)
Inventor
Christopher P. Adams
Neal R. COOK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arlington Vision LLC
Original Assignee
Arlington Vision LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arlington Vision LLC filed Critical Arlington Vision LLC
Publication of WO2021236579A1 publication Critical patent/WO2021236579A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • pirfenidone an antifibrotic agent used to treat idiopathic pulmonary fibrosis
  • amniotic membranes are used for treatment of cornea injuries, including chemical burns.
  • the amniotic membrane is the innermost avascular layer of the placenta about 0.02-0.05 mm thick located next to the fetus.
  • the AM consists of 3 different layers: the epithelium, basement membrane and stroma which further consists of three layers: the inner compact layer, middle fibroblast layer and the outermost spongy layer.
  • the AM has anti-inflammatory, anti-fibrotic, anti-angiogenic and anti-microbial properties. Additionally, it is transparent and lacks immunogenicity.
  • the mechanism through which AM causes healing is complex and involves a combination of factors including providing a substrate for growth of the regenerating ocular epithelia and providing anti-fibrotic, anti-inflammatory, anti- angiogenetic and anti-microbial properties.
  • fetal hyaluronic acid present in the AM stroma suppresses TGF b signaling with reduced expression of TGF b-1, b-2, and b ⁇ 3 isoforms in addition to reduced expression of TGF-Receptor P, which inhibits proliferation of corneal, limbal and conjunctiva! fibroblasts, which reduces scarring.
  • the presence of AM also inhibits expression of pro-inflammatory cytokines from the damaged ocular surface, e.g., interleukin (IL) 1a, IL-2, IL-8, interferon-g, tumor necrosis factor-b, basic fibroblast growth factor and platelet derived growth factor.
  • IL interleukin
  • the substrate of the AM could also promote regeneration of the epithelium by facilitating migration and differentiation, and preventing apoptosis.
  • AM is typically transplanted onto the cornea in the first week following an ocular surface burn. Using the AM can relieve pain, accelerate healing and reduce scarring. The surgery involves applying a patch of AM over the entire ocular surface up to the eyelid margins, which is a tedious and problematic procedure.
  • the AM is typically placed on the damaged epithelia and sutured. Based on the typical thickness of 0.02-0.05 mm for AM and approximate area of cornea, the implanted AM weights about 2-5 mg if it covers the entire cornea.
  • the epithelia side of the membrane faces away from the cornea with the idea that the AM will act as a substrate for the progenitor epithelial cells.
  • the surrounding 1-2 mm of the patient’s epithelium is debrided to facilitate growth of the regenerating epithelia over the amniotic membrane, effectively incorporating the AM inside the patient’s eye.
  • an AM larger in size than the defect is sutured far away from the edge of the damage.
  • the AM serves as a cover and the regenerating epithelia grows under the membrane.
  • the need for suturing the AM can be eliminated by using a commercial device, sold under the tradename PROKERA ® , which contains the AM mounted in a device that allows placing the lens on the eye without any sutures if is a cryopreserved AM mounted in a polycarbonate ring or an elastomeric band. Over time the membrane dissolves releasing components beneficial for healing. The device provides the benefits of AM-facilitated healing while allowing for ease of application to the eye. However, as the AM in the device dissolves, a fraction is lost to tear drainage. [0009] Another existing device uses dehydrated AM placed on the eye and covered with a soft contact lens to minimize the loss of AM to tear drainage. Based on the device’s 15 mm diameter, about 6 g or 18 mg of amnion is provided from a 35 micron or 100 micron thick device, respectively.
  • a conforming device conformer
  • the conformer is designed such that placing it on the cornea results in formation of a pool of liquid between the underside of the conformer and the cornea with limited leakage of the contents from inside the pool to outside the device.
  • the outer surface of the conformer is smooth to provide a suitable surface for a tear film to form thereon and an eyelid to glide over.
  • the amnion powder is typically deposited on the inner concavity of the conformer in a manner to be in close proximity to the cornea but without pushing the amniotic material onto the cornea.
  • the amnion powder is also deposited such that the deposited material can break apart and detach from the conformer after placement of the device on the eye. It is also a goal of the present invention to incorporate pharmaceuticals and/or stem cells into the device to enhance healing and provide other benefits, such as antibiotic activity.
  • an ocular device comprises a conformer having a concave surface and a convex surface and a layer of amniotic particles characterized by an average diameter less than or equal to 1 mm disposed on at least a portion of the concave surface, the convex surface, or both the concave surface and the convex surface.
  • the conformer is transparent and/or colorless.
  • the concave surface comprises a pocket circumscribed by a skirt, the pocket having a steeper curvature gradient than the skirt.
  • the amniotic particles are disposed within the pocket.
  • the amniotic particles are characterized by an average diameter between 1 micron and 1 mm, or between 10 microns and 0.5 mm, or between 20 mm and 0.5 mm, or between 25 microns and 250 microns, or between 50 microns and 100 microns.
  • the amniotic particles are nanoparticles characterized by an average diameter of 100 nm or less.
  • the amniotic particles are characterized by an average diameter between 100 nm and 5 nm, or between 75 nm and 10 nm, or 50 nm and 20 nm.
  • a mass of the amniotic particles is between 100 micrograms and 10 grams, or between 1 milligram and 5 grams, or between 10 milligrams and 1 gram, or between 50 milligrams and 0.5 gram, or between 0.1 grams and 0.3 grams.
  • the layer of amniotic particles consists of the amniotic particles.
  • the amniotic particles are dispersed within a hydrophilic polymer film.
  • the hydrophilic polymer may dissolve in biological fluid to release the amniotic particles.
  • a concentration of the amniotic particles in the hydrophilic polymer film is between 10% and 90% by weight, or between 20% and 80% by weight, or between 25% and 70% by weight, or between 30% and 50% by weight.
  • a pharmaceutical agent may be dispersed within the hydrophilic polymer film.
  • the pharmaceutical agent may be at least partially encapsulated within a microparticle, such as a microparticle formed from a biologically compatible polymer like PLA, PLGA, PEG or combinations thereof.
  • one or more pharmaceutical agents and/or amniotic particles are at least partially encapsulated within the conformer.
  • a conformer is a scleral contact lens, a rigid gas permeable contact lens, or a soft polymer contact lens.
  • an ocular device disclosed herein further comprises stem cells disposed on at least a portion of the concave surface, the convex surface, or both the concave surface and the convex surface.
  • the stem cells are present in a quantity between 100 and 100,000, or between 250 and 10,000, or between 500 and 5,000.
  • stem cells and/or amniotic particles are dispersed within a single layer formed by a single type of hydrophilic polymer film.
  • stem cells and/or amniotic particles are dispersed within separate layers, which may be formed by the same hydrophilic polymer or by different hydrophilic polymers.
  • an ocular device comprises a plurality of layers of amniotic particles, stem cells, or both amniotic particles and stem cells.
  • the plurality of layers may alternate, regularly or irregularly, between amniotic particles and stem cells, or between layers having amniotic particles of different diameters, and/or between layers having different concentrations of active ingredients (amniotic particles, stem cells, and/or pharmaceutical agents).
  • a layer of stem cells is disposed between the conformer and a layer of amniotic particles. In an embodiment, a layer of amniotic particles is disposed between the conformer and a layer of stem cells. In an embodiment, a conformer is disposed between a layer of stem cells and a layer of amniotic particles.
  • stem cells and amniotic particles are disposed at physically distinct locations on the conformer relative to one another.
  • stem cells and amniotic particles may be disposed at different locations on the same surface of the conformer, or stem cells and amniotic particles may be disposed on different surfaces of the conformer relative to one another.
  • an ocular device comprises a conformer having a concave surface and a convex surface and a layer of stem cells disposed on at least a portion of the concave surface, the convex surface, or both the concave surface and the convex surface.
  • an ocular device kit comprises at least one conformer having a concave surface and a convex surface and a vessel comprising amniotic particles and/or stem cells, and optionally one or more pharmaceutical agents, dispersed within a hydrophilic polymer solution.
  • a method of making an ocular device comprises providing a conformer having a concave surface and a convex surface, mixing amniotic particles and/or stem cells in a solvent to form a dispersion, applying the dispersion to at least a portion of the concave surface, the convex surface, or both the concave surface and the convex surface, and removing the solvent from the dispersion to form a dry layer of amniotic particles on the conformer.
  • the step of mixing comprises sonicating.
  • the step of removing the solvent comprises air drying, reducing pressure and/or heating.
  • FIG. 1 shows side-by-side photographs of a conformer containing amniotic powder (“AP”) and the same conformer containing sonicated powder dispersed in a hydroxy propyl methyl cellulose (HPMC) film.
  • AP amniotic powder
  • HPMC hydroxy propyl methyl cellulose
  • FIG. 2 shows a convex surface of a conformer blank.
  • FIG. 3 shows a concave surface of the conformer blank of FIG. 2.
  • FIG. 4 shows a conformer containing amniotic powder (“AP”), according to an embodiment.
  • FIGS. 5, 6, and 7 show various angles of a conformer containing amnion powder dispersed in a saline film, according to an embodiment.
  • Amniotic Membrane (AM) - AM is the innermost avascular layer of the placenta, about 0.02-0.05 mm thick located next to the fetus.
  • Amniotic Powder (AP) - AP is obtained by finely dividing dried AM into particles with an average diameter between 10 nm and 1 mm.
  • Conformer - A conformer is the device into or onto which the AP is deposited.
  • a conformer has a concave surface and a convex surface, with the concave surface facing the anterior surface of a patient’s cornea when the device is placed on the eye of the patient.
  • the AP is deposited on the concave surface (e.g., when corneal repair is desired), on the convex surface (e.g., when the backside of the eyelid is damaged), or on both surfaces (e.g., when multiple areas within the ocular anatomy are damaged).
  • amniotic Conformer (AC) - An amniotic conformer is a conformer containing a film of AP on at least one surface of the conformer.
  • Embodiments of the present disclosure relate to methods for preparing and using a device that brings AP and/or stem cells in proximity to damaged ocular anatomy while minimizing loss of active ingredients due to leakage from the device.
  • the AM is converted to AP by any suitable processing method including, but not limited to, milling, grinding, chopping, freeze drying and spray drying.
  • the AP is hydrated by addition of saline ranging from about 1 % to 25% by weight of the AP, about 1 % to 15% by weight of AP, or about 1-5% by weight of the AP to form a concentrated slurry.
  • additional components are added to the slurry to increase viscosity of the slurry.
  • the slurry is dispersed in the concavity of a conformer (CR), followed by drying, e.g., in a vacuum oven or incubator, to evaporate liquid from the slurry.
  • CR conformer
  • the evaporation typically occurs in a few hours, but could be sped up by controlling the temperature and/or pressure of the drying process. As the slurry dries, the AP particles stick together to form a film in the concavity of the conformer. This device with the film of AP on the conformer is called an “Amniotic Conformer or AC”.
  • the mass of AP deposited in a conformer is 2-5 mg to be comparable to the mass of a single layer of amniotic membrane covering the cornea.
  • the mass of AP is increased to 5-50 mg to provide additional mass, which may be useful for severe injuries.
  • the mass of AP is reduced to 0.1-2 mg, or to 0.01 - 0.1 mg, which may be sufficient for less severe injuries, particularly because the AP and its components are retained on the cornea for extended periods by the conformer.
  • the AM is converted to a dispersion by adding water or saline followed by sonicating to reduce the particle size to tens to several hundred nanometers. Sonication may be carried out, for example, at 700 W for 5 minutes with intermittent cycles of 30 s sonication followed by 1 min of no-sonication. Stabilizers, such as surfactants or polymers, can be added to the AM dispersion as well. Typically, the amount of water or saline added for sonication will be such that the mass of AM is about 1-10% of the total weight. In other embodiments, 10-25% AM can be added to the water or saline prior to sonication.
  • Stabilizers such as surfactants or polymers
  • the hydrophilic polymer carboxyl methyl cellulose (CMC) is added at 1-10% (w/w) to the sonicated AM to produce a viscous AM suspension or hydrogel.
  • other hydrophilic polymers such as hydroxy propyl methyl cellulose (HPMC), agarose, poly vinyl alcohol (PVA), poly ethylene glycol (PEG), and the like are added to the sonicated AM to form a viscous AM suspension.
  • the polymer loading in the suspension is 10- 25% w/w.
  • the polymer is added to the mixture of water/saline and AM prior to sonication.
  • stem cells are mixed with amniotic particles and/or hydrophilic polymer and applied to a conformer without undergoing sonication.
  • FIG. 1 shows side-by-side photographs of a conformer containing amniotic powder (“AP”) and the same conformer containing sonicated powder dispersed in a hydroxy propyl methyl cellulose (HPMC) film.
  • the hydrogel film is transparent due to the nanosize of the amnion particles while the amniotic powder film is opaque due to the larger size of the particles.
  • FIG. 2 shows a convex surface of a conformer blank.
  • FIG. 3 shows a concave surface of the conformer blank of FIG. 2.
  • FIG. 4 shows a conformer containing amniotic powder (“AP”).
  • FIGS. 5, 6, and 7 show various angles of a conformer containing amnion powder dispersed in a saline film, according to an embodiment.
  • the suspension of nanoparticles containing 1-10% nanoparticles is freeze dried to manufacture powder.
  • spray drying can be used to form the powder.
  • the powder is then converted to a slurry by addition of a small amount, typically 1-5% (w/w), water or saline or a physiological buffer.
  • the slurry is placed in the concavity of the conformer and/or on the convex surface of the conformer, followed by placing the AP-loaded conformer into a vacuum oven or incubator to evaporate the liquid from the slurry.
  • the evaporation typically occurs in a few hours but could be sped up by controlling the temperature and/or pressure while drying. As the slurry dries, the AP particles stick together to form a film.
  • the viscous polymer suspension is placed in the concavity of the conformer and/or on a convex surface of the conformer, followed by placing the conformer into a vacuum oven or incubator to evaporate liquid in the polymer suspension.
  • the evaporation typically occurs in about a day but controlling the temperature and/or pressure while drying could speed it up. Drying of the polymer suspension results in formation of a thin film of the hydrophilic polymer with amnion nanoparticles encapsulated within the film.
  • the amnion-loaded film is transparent and the presence of the amnion-loaded film does not impact the transparency of the conformer.
  • the AP is sprayed directly onto a surface of the conformer.
  • the AP is deposited onto the conformer via ink-jet printing, where AP and/or stem cells are a component of the ink. In both methods, the mass of amnion deposited on the conformer is in the range of 2-5 mg, or in the range 5-50 mg to provide additional mass which may be useful for severe injuries.
  • the mass is reduced to 0.1-2 mg and to 0.01 - 0.1 mg.
  • the conformer is rotated about its central axis during the drying process to obtain a fine film on the surface of the conformer.
  • the pH of the slurry or suspension of nanoparticles is maintained in the range of 5-7 and osmolarity is maintained at 300 mOs by addition of salt to minimize the potential for discomfort to the patient.
  • Corneal scarring / fibrosis is the major sequel to several forms of insults to the cornea, including alkali burn. Loss of corneal transparency is the second highest cause of vision impairment, therefore appropriate management to prevent corneal fibrosis is imperative.
  • There is yet no specific therapy in clinical practice to address corneal fibrosis but researchers have previously identified pirfenidone nanoformulation drops as a promising therapy to prevent corneal scarring. They have also reported the anti-inflammatory and antifibrotic effects of pirfenidone in prevention of fibrosis leading to proliferative vitreoretinopathy. Thus, inclusion of pirfenidone within the formulations disclosed herein may be beneficial.
  • pirfenidone (1 mg/mL) is added to the suspension of AM nanoparticles containing polymer, followed by one of the processes described above to form a polymeric film containing amnion nanoparticles and dissolved pharmaceutical.
  • pirfenidone is encapsulated within PLGA nanoparticles or microparticles to allow for extended release of the drug.
  • Drug- loaded PLGA particles can be produced using a double emulsion approach. Overall, the suspension will contain 5-20% polymer, 1-10% amnion nanoparticles, and 1-5% PLGA nanoparticles which contain drug at a loading of 0.1-10%. Many ophthalmic drugs can bind to the surface of the amnion particles resulting in an increase in drug loading and/or release duration.
  • drug-containing PLGA particles are added to the AP and/or stem cell slurry, followed by one of the processes described above to form an amnion film.
  • other pharmaceuticals are incorporated into the device such as antibiotics (levofloxacin, moxifloxacin); steroids such as dexamethasone; analgesics such as ketorolac and lidocaine.
  • antibiotics levofloxacin, moxifloxacin
  • steroids such as dexamethasone
  • analgesics such as ketorolac and lidocaine.
  • multiple pharmaceuticals can be incorporated into PLGA particles and then into the amnion film.
  • a typical composition will have PLGA particles with 1-10% drug loading, and 1- 20% of the PLGA particles in an AM nanoparticle and/or stem cell suspension.
  • stem cells and stem cell solutions are added to the conformer with the nanoparticle suspensions.
  • the stem cells are added in a concentration of from 100-100,000 cells per 100 pi of phosphate buffered saline
  • the conformer is shaped to have an anterior side that faces the eyelids and the posterior side that faces the cornea.
  • the radius of curvature of the posterior side must be steeper than that of the cornea so that placing the conformer on the cornea leads to formation of a vault in the central cornea with the edges of the conformer resting beyond the limbus, on the conjunctiva, to minimize the potential for discomfort.
  • the central section of the conformer should preferably be semi- spherical to create a pocket when the conformer is placed on the eye, and the central section is surrounded by a skirt of flatter curvature to conform to the shape of the sclera.
  • the thickness of the vault i.e., the spacing between the posterior surface of the conformer and the cornea should be at least 50 microns, and preferably 50-400 microns to accommodate the amniotic film therebetween. A thickness of larger than 400 microns could lead to reduced oxygen permeation that may inhibit the healing process.
  • a diameter of the conformer should be at least 6 mm and preferably 6-16 mm. These dimensions are only guides and the actual dimensions may depend on the specific would and shape of the patient’s cornea.
  • the anterior surface of the conformer must be smooth to allow gliding of the eyelid without discomfort.
  • the conformer is a rigid gas permeable contact lens. In an embodiment, the conformer is soft allowing the vault or pocket to be compressed, resulting in intimate contact of the amnion film with the cornea. In an embodiment, the conformer is a soft silicone-hydrogel contact lens. In an embodiment, the pharmaceuticals are incorporated into the soft contact lenses prior to forming the amnion film in the concavity.
  • the amnion nanoparticles are incorporated directly inside the soft contact lens by soaking the contact lens in the amnion nanoparticle suspension for about 7 days.
  • dried amnion nanoparticles are dispersed in an organic liquid such as ethanol, followed by soaking the soft contact lens. The lens expands considerably in the ethanol allowing diffusion of nanoparticles into the lens.
  • amnion nanoparticles are added to a monomer mixture followed by polymerization to form a soft contact lens having amnion nanoparticles dispersed therein.
  • hydroxymethyl methacrylate is added to the amnion nanoparticle suspension at 20-50% w/w, along with 2% crosslinker and 0.1% initiator, followed by polymerization in a mold to form a contact lens loaded with amnion nanoparticles.
  • the contact lens is made of dissolvable material such as HPMC.
  • vitamin E is loaded into a soft contact lens along with one or more pharmaceuticals and amniotic nanoparticles to increase the release duration of the loaded drugs.
  • Vitamin E diffusion barriers may be incorporated into contact lenses at 0-30% (w/w in dried lens) to increase the drug release duration.
  • vitamin E and drug-loaded lenses are used as a bandage lens over an amniotic membrane to combine the beneficial effects of the amniotic material and the drugs.
  • the device in this case is a package comprising a dehydrated AM and a fully hydrated contact lens loaded with vitamin E and ophthalmic drugs such as levofloxacin, dexamethasone, ketorolac, etc.
  • An amniotic conformer device may be packaged and then sterilized via ebeam.
  • a medical professional opens the package, fills the concavity of the device with a separately packaged AM nanoparticle suspension (optionally comprising additional agents), and then places the device on a patient’s eye.
  • the solution accompanying the amniotic conformer comprises buffered saline.
  • hydrophilic polymer such as carboxyl methyl cellulose (CMC) is added to the accompanying solution at 0.1-10% (w/w) to increase the viscosity of the fluid which will assist in lubrication and potentially increasing comfort after placing an amniotic conformer on a patient’s eye.
  • the AM nanoparticle suspension contains nanoparticles of amniotic material at 0.1- 10% manufactured by sonication or homogenization of an amniotic powder.
  • the AM nanoparticle suspension includes amniotic nanoparticles at 0.1-10% and hydrophilic polymers at 0.1-10%.
  • the AM nanoparticle suspension contains one or more surfactants, such as pluronics, to stabilize the amniotic nanoparticle suspension.
  • the AM nanoparticle suspension includes drugs, such as pirfenidone, to aid wound healing.
  • drugs such as antibiotics (levofloxacin, moxifloxacin); steroids such as dexamethasone; analgesics such as ketorolac, lidocaine, are added to the AM nanoparticle suspension.
  • one or more drugs can be incorporated into PLGA particles, which are then added to the AM nanoparticle suspension.
  • Stem cells can be incorporated into a hydrogel and deposited on the conformer to form a device for delivering stem cells to the cornea.
  • the amnion film in the conformer breaks up after exposure to tears to release the amniotic particles.
  • In vitro studies of the amnion film conformer formed by evaporation of the slurry demonstrated that the film falls apart slowly releasing the amnion into the fluid.
  • the concavity of the conformer loaded with amnion was filled with an aqueous solution, and placed on a vibrating stage to simulate the motion inside the eye.
  • the amnion slurry is then allowed to dry to form the film.
  • the dried device is then filled with the aqueous solution to test in vitro how the deposited film breaks releasing the amniotic material.
  • the film falls apart gradually releasing the material into the fluid.
  • the film starts to break around 40 min and completely disintegrates in a few hours. Experiments were also conducted in vivo. It was discovered that upon insertion of the conformer with the film deposited from slurry, the film falls apart faster than in vitro. The film broke apart into many pieces in about 20-30 min, which improved the patient’s vision considerably. Visual acuity was 20/80 after 2 minutes improving to 20/30 after 35 minutes.
  • Wagoner MD Chemical injuries of the eye: current concepts in pathophysiology and therapy. Surv Ophthalmo. 1997;41:275-313.
  • Maher TM Pirfenidone in Idiopathic Pulmonary Fibrosis. Drugs Today (Bare). 2010;46:473-482. doi:10.1358/dot.2010.46.7.1488336.
  • ranges specifically include the values provided as endpoint values of the range and all the integer values of the range.
  • a range of 1 to 100 specifically includes the end point values of 1 and 100. It will be understood that any subranges or individual values in a range or subrange that are included in the description herein can be excluded from the claims herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Medicinal Preparation (AREA)

Abstract

Les dispositifs oculaires comprennent un conformère ayant une surface concave et une surface convexe avec une couche de particules amniotiques, caractérisées par un diamètre moyen inférieur ou égal à 1 mm, et/ou des cellules souches disposées sur au moins une partie de la surface concave, de la surface convexe, ou à la fois de la surface concave et de la surface convexe, ainsi que des procédés de fabrication et d'utilisation de tels dispositifs.
PCT/US2021/032878 2020-05-18 2021-05-18 Administration de composants de membrane amniotique à des épithéliums oculaires pour la cicatrisation de plaies Ceased WO2021236579A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063026249P 2020-05-18 2020-05-18
US63/026,249 2020-05-18

Publications (1)

Publication Number Publication Date
WO2021236579A1 true WO2021236579A1 (fr) 2021-11-25

Family

ID=78707523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/032878 Ceased WO2021236579A1 (fr) 2020-05-18 2021-05-18 Administration de composants de membrane amniotique à des épithéliums oculaires pour la cicatrisation de plaies

Country Status (1)

Country Link
WO (1) WO2021236579A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181240A1 (en) * 2002-03-14 2004-09-16 Tseng Scheffer C.G. Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes
US20100036488A1 (en) * 2008-04-04 2010-02-11 Forsight Labs, Llc Therapeutic device for pain management and vision
US8440217B1 (en) * 2005-06-15 2013-05-14 Mawaheb M. EL-Naggar Method and system with contact lens product for treating and preventing adverse eye conditions
US20140033808A1 (en) * 2012-08-01 2014-02-06 The Penn State Research Foundation High-efficiency separation and manipulation of particles and cells in microfluidic device using surface acoustic waves at an oblique angle
US20160220485A1 (en) * 2012-07-02 2016-08-04 Celso Tello Amniotic or placental preparation and device for ophthalmic use as a dressing to enhance healing
US20180110900A1 (en) * 2016-08-21 2018-04-26 Michael S. Korenfeld Therapeutic Applications of Honey and Amniotic Membrane for the Treatment of Disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040181240A1 (en) * 2002-03-14 2004-09-16 Tseng Scheffer C.G. Amniotic membrane covering for a tissue surface and devices facilitating fastening of membranes
US8440217B1 (en) * 2005-06-15 2013-05-14 Mawaheb M. EL-Naggar Method and system with contact lens product for treating and preventing adverse eye conditions
US20100036488A1 (en) * 2008-04-04 2010-02-11 Forsight Labs, Llc Therapeutic device for pain management and vision
US20160220485A1 (en) * 2012-07-02 2016-08-04 Celso Tello Amniotic or placental preparation and device for ophthalmic use as a dressing to enhance healing
US20140033808A1 (en) * 2012-08-01 2014-02-06 The Penn State Research Foundation High-efficiency separation and manipulation of particles and cells in microfluidic device using surface acoustic waves at an oblique angle
US20180110900A1 (en) * 2016-08-21 2018-04-26 Michael S. Korenfeld Therapeutic Applications of Honey and Amniotic Membrane for the Treatment of Disease

Similar Documents

Publication Publication Date Title
Morrison et al. Advances in ophthalmic drug delivery
Pal Kaur et al. Ocular preparations: the formulation approach
US10583221B2 (en) Method of corneal transplantation or corneal inlay implantation with cross-linking
US10881503B2 (en) Method of corneal transplantation or corneal inlay implantation with cross-linking
Kumar et al. Ocular inserts: A novel controlled drug delivery system
Karthikeyan et al. The concept of ocular inserts as drug delivery systems: An overview
JP2019504855A (ja) 非侵襲性眼内薬物送達技法
US11045352B2 (en) Methods for treatment of dry eye and other acute or chronic inflammatory processes
TW201639592A (zh) 眼用組合物及其使用方法
US20160166701A1 (en) Delivery composition for topical applications and injections and ophthalmic formulations, methods for manufacturing thereof, and methods for delivery of a drug-delivery composition
Wang et al. Lollipop‐inspired multilayered drug delivery hydrogel for dual effective, long‐term, and NIR‐defined glaucoma treatment
US11338059B2 (en) Method of corneal and scleral inlay crosslinking and preservation
Zidan et al. Medicated ocular bandages and corneal health: potential excipients and active pharmaceutical ingredients
JP2002543143A (ja) 角膜の瘢痕、混濁およびかすみを無くす生化学的方法
Yan et al. Advances in adhesive hydrogels applied for ophthalmology: An overview focused on the treatment
Das et al. Drug delivery to eye: Special reference to nanoparticles
Lee et al. Advances in ophthalmic drug delivery technology for postoperative management after cataract surgery
US20200345896A1 (en) Method Of Corneal Transplantation Or Corneal Inlay Implantation With Cross-Linking
KR20050057169A (ko) 항염증 특성을 갖는 안구조직 치료용 마이크로스피어를 포함하는 조성물
Anisimova et al. Five-year results of non-penetrating deep sclerectomy with demineralized cancellous bone xenogenically derived collagen glaucoma implant
WO2021236579A1 (fr) Administration de composants de membrane amniotique à des épithéliums oculaires pour la cicatrisation de plaies
Tekko et al. Microneedles for ocular drug delivery and targeting: challenges and opportunities
Rao et al. Carbodiimide crosslinked decellularized lenticules as a drug carrier for sustained antibacterial eye treatments
Palani et al. Ocular drug delivery: A Review
Tandias et al. Innovation in Keratoprostheses: A Review of Modern Devices and Strategies for Preventing and Managing Complications

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21809264

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21809264

Country of ref document: EP

Kind code of ref document: A1